2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neuroblastoma
10
Melanoma
8
Neoplasm Metastasis
6
Breast Neoplasms
6
Ganglioneuroblastoma
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Multiple Myeloma
4
Lymphoma
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Uveal Melanoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Follicular
2
Leukemia
2
Gliosarcoma
2
Glioma
2
Carcinoma, Intraductal, Noninfiltrating
2
Astrocytoma
2
Interventions
pembrolizumab
29
avelumab
21
Nivolumab
20
Ipilimumab
10
Radiotherapy
9
Cyclophosphamide
9
atezolizumab
8
cemiplimab
7
fludarabine
6
Specimen Handling
6
durvalumab
5
aldesleukin
5
Radiation
5
Magnetic Resonance Spectroscopy
5
Interleukin-2
5
Biopsy
5
talimogene laherparepvec
4
ALT-803
4
poly ICLC
3
Radiosurgery
3
Etoposide
3
Cisplatin
3
Carboplatin
3
CTLA-4 Antigen
3
Bevacizumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
domatinostat
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled